Preclinical review highlights nanoparticle imaging agents for fluorescence-guided breast cancer surgery, indicating potential for clinical translation despite safety and clearance challenges.
preclinical breast cancer models, and reported clearance pathways and safety profiles. Despite the remaining translational challenges, significant progress is being made in the preclinical development of innovative nanoparticle imaging agents for fluorescence-guided surgery of breast cancer, which demonstrates their potential application for clinical studies.
No takes yet. Share an insight, caveat, or question.
Zahraie et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: